



#TeamQLDBIO

BIO International Convention 2024

Delegate directory



Connect with us @GrowingQld



Queensland, Australia – Bright Minds. Bright Bio-future.

Australia's \$250-billion life sciences sector is one of the largest in the southern hemisphere and constantly growing. It's home to more than 2,600 organisations. Our high-quality and innovative healthcare system is envied around the world and supports a world-class medical research sector.

Australia is one of the top 10 countries in the world for contributions to life sciences research and Queensland, Australia was the incubator for the Gardasil® vaccine for human papillomavirus (HPV).

The Australian Government provides support at each phase of the innovation pathway, including:

- The A\$20 billion Medical Research Future Fund to address emerging health needs.
- The A\$15 billion National Reconstruction Fund for manufacturing, with A\$1.5 billion earmarked for medical manufacturing.
- The A\$500 million Biomedical Translation Fund, which supports biomedical research commercialisation.
- A Research and Development Tax Incentive, which provides a tax offset of up to 43.5% on eligible R&D expenditure.

With a pro-business government; proximity to Asian economies; a well-educated and skilled workforce; and enviable liveability, Queensland is the perfect place to invest.

As Queensland prepares to welcome the world for the 2032 Olympic and Paralympic Games, it's time for international investors to put themselves in a win-win position and choose Queensland as their preferred location.

Queensland life sciences: global leaders

Queensland is recognised as a leading biomedical industry hub for the Asia-Pacific region, offering globally recognised infrastructure for research, translation, manufacture and supply to the highest international standards.

The sector has the full backing of the Queensland Government through its [Queensland Biomedical 10-Year Roadmap and Action Plan](#), which sets out how we are going to grow, support and attract biomedical enterprises and invest in state-of-the-art facilities, talent and partnerships.

Our unique health and knowledge precincts combine hospitals delivering high-quality care, researchers conducting leading-edge research and innovative companies developing new products.

US medtech giant Stryker and global healthcare and pharmaceutical company Sanofi have chosen to establish a strong R&D presence in Queensland.

At the [Translational Science Hub](#), Queensland's world-class researchers connect with Sanofi scientists in France and the US, placing Queensland at the forefront of global mRNA vaccine development and biomedical research.



Queensland
Government

\$361m Private manufacturing R&D investment annually	\$534.3m Estimated export value	\$2.1b+ Economic contribution in gross value-added
12 Research-focused universities, with four in the world's top 250	20% 1 in 5 Australian clinical trials take place in Queensland	\$1.3m Low payroll tax (4.75%), high exemption threshold

Clinical trials

Queensland is a global hub for cutting-edge clinical research and development, offering a one-stop shop for seamless end-to-end clinical trial solutions. We are an extremely attractive location to undertake clinical trials.

Our robust regulatory and tax environment, plus access to world-class researchers and clinicians, creates an ideal market for prototyping, testing, conducting clinical trials, and manufacturing. With modern translational facilities and fast, pragmatic regulatory pathways, our infrastructure is a commercially focused platform for growth.

By choosing Queensland, you can increase the speed of your product R&D. Including southern hemisphere sites means you can access all-year-round recruitment of patients suffering from seasonal ailments, including influenza and allergies, as well as those diagnosed with respiratory and tropical diseases.

Each year, Queensland conducts thousands of clinical trials across hundreds of sites around the state. In 2022–2023 alone, there were more than 320 new clinical trials conducted in Queensland Health, which is the largest provider of clinical trials in the state.

Queensland is also leading the country with its teletrial capability. Teletrial is a proven model that uses telecommunication technology to connect clinical trial clusters to improve access to and participation in clinical trials for regional, rural, and remote Australians.

Further, Queensland is internationally recognised for its highly trained clinical workforce and the high-quality research data produced by its experienced research teams. The state hosts a variety of contract research organisations, health economics, financial and legal services, imaging facilities, genomic services, laboratory services, Good Manufacturing Practice (GMP) manufacturers, and regulatory consultants.

Queensland is part of a nationwide approach which has embraced a fast and pragmatic regulatory pathway for conducting clinical trials. The regulatory framework allows rapid clinical trials start-up through streamlined processes under the Clinical Trials Notification (CTN) scheme administered by the Therapeutic Goods Administration (TGA).

Australian clinical trial data is accepted by international regulatory agencies including the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

As you can see, Queensland is in an ideal position to continue to attract international companies and to build sovereign capability in a number of areas including the development, manufacture, and delivery of vaccines.

There has never been a better time to make the decision to come to Queensland!

Why choose Queensland for your clinical trials

One-stop shop for seamless end-to-end clinical trial solutions.	Australia is 60% cheaper than the US with the 43.5% “cash back” under the research and development (R&D) tax incentive.	Australia is ~3x shorter than in the US and ~2x shorter than in the UK for phase 1 clinical trials	US FDA and Europe EMA accept Australian clinical testing, making Australia attractive grounds for Asia-based CROs
---	---	--	---

The Queensland Clinical Trials Portal provides information on conducting clinical trials in Queensland including a comprehensive directory of clinical trials sites, their capabilities and a directory of service providers at <https://www.clinicaltrialsqld.com.au/>.

Our delegates

Queensland Government

The Queensland Government has industry development and investment attraction focussed departments to build Queensland's biomedical ecosystem.

Department of State Development and Infrastructure

www.statedevelopment.qld.gov.au/industry/critical-industry-support/biomedical

About us

The Department of State Development and Infrastructure is a Queensland Government department that brings together the functions of infrastructure with economic, regional and industry development to create great places to live, work and play in Queensland. The department is responsible for Queensland's Biomedical 10-Year Roadmap and Action Plan, setting out our vision for Queensland to be a globally competitive Asia-Pacific biomedical industry hub by 2027.

Contact us

Ms Denise Johnston
Executive Director
denise.johnston@dsdilgp.qld.gov.au
+61 447 060 289

Trade and Investment Queensland

www.tiq.qld.gov.au/

About us

Trade and Investment Queensland is the Queensland Government's dedicated global business agency, helping Queensland exporters take their products to world markets and promoting Queensland as the perfect place for investment.

TIQ facilitates personalized connections to drive global business opportunities for export markets, and attract international investors, buyers and talent to Queensland, Australia.

Contact us

Ms Viki Forrest
Queensland Senior Trade and Investment
Commissioner – Americas
Viki.forrest@tiq.qld.gov.au
+1 415 309 7068

Mr Jas Sanghera
Principal Trade and Investment Advisor
jas.sanghera@tiq.qld.gov.au
+61 458 581 014

Ms Alita Singer
Director, Investment
Alita.singer@tiq.qld.gov.au
+1 646 530 4418

Mrs Aneis Reed
Senior Manager, Trade
aneis.reed@tiq.qld.gov.au
+1 917 751 9136

Queensland Investment Corporation

QIC Real Estate

www.qicre.com

About us

QIC is a trusted investment manager and adviser providing risk adjusted returns for the clients it serves. As one of the nation's leading institutional investment managers, QIC delivers alternative real asset solutions across infrastructure, real estate, private debt, private equity and natural capital, in addition to a liquid market offering, for approximately 115 Australian and global clients. It also acts as the Queensland Government's independent investment advisor, managing a fully-funded Defined Benefit scheme and the Queensland Future Fund, both of which deliver on the State's long-term investment objectives. QIC has A\$106bn in assets under management (as at 31 Dec 2023) and are headquartered in Brisbane, Australia, with offices in Sydney, Melbourne, New York, San Francisco, London and Singapore.

Cross River Rail

QIC has been appointed precinct developer for the above-ground Cross River Rail precincts at Boggo Road, Woolloongabba, Roma Street and Albert Street, leading the implementation of the Queensland Government's Precincts Delivery Strategy for the benefit of Queensland. Brisbane is having a coming-of-age moment unprecedented in recent decades. Our city is revolutionising before our eyes into a truly global city with its own distinctive character, capable of holding its own on the world stage. At QIC, we're thrilled to be a part of this metamorphosis.

This opportunity is only possible due to the exceptional work of the Queensland Government and the Cross River Rail Delivery Authority, who delivered the CRR Precincts Delivery Strategy — a key enabler for a development of this nature. QIC has over 30 years' experience in asset stewardship and delivering value for Queensland, with long term real estate investment and operational capability aimed at driving value. We have a strong track record creating urban destinations and vibrant neighbourhoods that power local economies, and will draw on this experience to develop the above-ground precincts. Most importantly, we understand space — civic and commercial space, green space, and public realm and community space — and what is required to achieve these by putting people at the heart of our planning. We then apply this expertise when delivering infrastructure, while also applying a disciplined commercial lens on our State's long-term investment objectives.

Contact us

Mr Chris Brown
Cross River Rail Precincts Director
cbrown01@qic.com
+61 400 319 545

Ms Erin Clark
Boggo Road Development
eclark@qic.com
+61 490 442 279

Queensland universities and research institutions

Queensland is home to world class universities, research and infrastructure.

Griffith University

www.griffith.edu.au

Since 1975, our teaching and research have been focused on addressing the most important social and environmental issues of our time. Today, that mission is as relevant as ever.

Social and environmental responsibility drive everything we do, from pioneering teaching in modern Asian studies and environmental science to our long-time support for First Peoples, social justice and sustainable practices.

Consistently ranking in the top 2 per cent of universities globally, our degrees are designed with industry in mind, the future in our sights, and social impact at heart.

With more than 55,000 students, our community spans five campuses across South East Queensland plus our Digital campus, complemented by a global alumni network of over 200,000 graduates.

Griffith Enterprise

www.griffith.edu.au/griffith-enterprise

About us

Griffith is one of Australia's leading research universities

Working in our world-class research centres, institutes and schools, our researchers are driven to better understand our world and improve people's lives. Our research strengths span a broad spectrum of areas, from chronic diseases to criminology and Asian politics to the arts. Griffith researchers are at the forefront of discovery.

Our experts work in research centres developing new knowledge in a range of specialist areas including medicine and healthcare, emerging technologies, social innovations, culture, learning and the arts, the environment, and governance and policy development. Most of these institutes and centres align with our four academic groups, with their cutting-edge research helping to inform our degrees, allowing students to gain the latest knowledge and learn alongside people making history in a wide range of research fields.

Contact us

Dr Mark Ashton
Director
m.ashton@griffith.edu.au
+61 410 601 970

Dr Declan Gorman
Senior Business and Innovation Associate
D.gorman@griffith.edu.au
+61 409 396 134

Griffith Institute for Drug Discovery

www.griffith.edu.au/institute-drug-discovery

About us

GRIDD is a world-class research facility, that offers unique resources and draws on a global network of partners to target the world's most devastating diseases. GRIDD is a Griffith University research institute with a focus on early-stage and pre-clinical drug discovery. GRIDD's aim is to utilise its unique resources, dedicated researchers and international partnerships to drive the discovery and development of revolutionary new treatments to improve human health and wellbeing.

Our discovery platforms include:

- Native mass spectrometry*
- High throughput screening and imaging*
- Small molecule hit identification
- Cell factories and biopolymers

Queensland delegate directory

- Nuclear magnetic resonance.

At Compounds Australia we have Australia's only dedicated compound management facility*

- 1.5 million compounds
- Compound libraries available in assay-ready plates*
- Pharma-like acoustic dispensing.

NatureBank with internationally unique biota derived from Australian marine invertebrates, plants and fungi,

And screening libraries of more than 125,000 plant extracts and fractions.

Our novel research tools include:

- Oligonucleotide synthesis
- Cell lines and animal models
- Virus-like particles
- Advanced functional materials.

Biobanks

- Queensland Parkinson's Project
- Saliva and liquid biopsy bank.

Contact us

Dr Nagaraj Gopisetty

Strategy and Business Development Manager

n.gopisettyvenkata@griffith.edu.au

+61 408 239 010

Institute for Glycomics

www.griffith.edu.au/institute-glycomics

About us

The Institute for Glycomics is a world leader in the discovery and development of next-generation drugs, vaccines and diagnostics that fight diseases of global impact.

Established in 2000, we're the only institute of its kind in Australia and one of only a handful in the world.

We engage globally with industry, philanthropic organisations, government and other premier research institutes to build the human capital driving healthcare solutions that address some of the world's most intractable diseases.

Our multidisciplinary research primarily targets prevention and cures for infectious diseases, cancer and neurodegenerative disorders, with a focus on translational research.

Contact us

Ms Eloise Keefe

Business Manager (Commercial)

e.keeffe@griffith.edu.au

+61 455 529 283

QIMR Berghofer Medical Research Institute

www.qimrberghofer.edu.au

About us

QIMR Berghofer Medical Research Institute (QIMR-B) is an independent medical research institute, with an outstanding and established track record of delivering internationally leading health and biomedical breakthroughs over almost eight decades.

Its performance has been underpinned by excellence and impact, contributing to improved health outcomes.

Its collaborative research programs in cancer, infectious diseases, chronic inflammation, genetics of disease, population health, mental health and neuroscience address the foremost health challenges in the region and the world.

For over two decades, Q-Gen Cell Therapeutics at QIMRB has been pivotal in translating cellular immunotherapy research into early-phase clinical trials, collaborating with global partners to develop treatments for cancer, infectious diseases, and autoimmune disorders.

Our TGA-approved GMP manufacturing facility, Q-Gen Cell Therapeutics, plays a vital role in providing potentially life-saving cell therapies to critically ill patients through the TGA's Special Access Scheme.

In response to escalating global demand for trusted partners in clinical trials and innovative solutions, QIMR Berghofer proudly extends its hand in collaboration. We welcome partnerships with biotech, pharma, universities, and medical research institutes worldwide, offering expertise in planning, preparation, and prevention of life-threatening diseases. Together, we aim to foster strong institutional collaborations, building a global ecosystem for knowledge exchange and mentoring opportunities.

Contact us

Professor Fabienne Mackay
Director and CEO
fabienne.mackay@qimrberghofer.edu.au
+ 61400202257

Dr Robert McLachlan
Acting Chief Commercial Officer
robert.mclachlan@qimrberghofer.edu.au
+61 407 371 096

Mrs Tamanna Monem
Head of Growth and Partnerships
tamanna.monem@qimrberghofer.edu.au
+61 472 707 075

Dr Dale Pavlovski
Industry Engagement Manager
dale.pavlovski@qimrberghofer.edu.au
0419981871

Queensland University of Technology

www.qut.edu.au

QUT has forged an enviable reputation as "the University for the Real World" leading to its inclusion in THE (Times Higher Education) and QS World University Rankings as one of the top 200 universities in the world. Integral to this reputation are the many industry partnerships which underpin our research platform, working to fulfil many of the United Nations Sustainable Development Goals, including renewable energy, food security, educational development, climate and health.

QUT holds particular strengths in genomics and personal health, biomedical technologies (joint biomechanics, cell and tissue engineering, medical devices), microbiome research, agriculture and bioeconomy (bananas, biofuels, synthetic biology), robotics and AI, data science, digital media.

Faculty of Health, Centre for Genomics and Personalised Health

About us

The aims of the Centre for Genomics and Personalised Health are to translate knowledge from genomics research to improve human health, by discovering better methods of diagnosing disease, developing targeted treatments based on genetics, and training the next generation of translational genomics scientists.

Our research spans the design, development, and application of methods for genomic discovery, analysis and translation to advance genomics-driven healthcare and drive outcomes in the real world of clinical and personalised health.

Contact us

Professor Lyn Griffiths
Director
lyn.griffiths@qut.edu.au
+61 417 702 256

Dr Mark Adams
Senior Research Fellow
mn.adams@qut.edu.au
+61 401 822 137

Business Development

About us

QUT has forged an enviable reputation as "the University for the Real World" leading to its inclusion in THE (Times Higher Education) and QS World University Rankings as one of the top 200 universities in the world. Integral to this reputation are the many industry partnerships which underpin our research platform, working to fulfil many of the United Nations Sustainable Development Goals, including renewable energy, food security, educational development, climate and health.

QUT holds particular strengths in genomics and personal health, biomedical technologies (joint biomechanics, cell and tissue engineering, medical devices), microbiome research, agriculture and bioeconomy (bananas, biofuels, synthetic biology), robotics and AI, data science, digital media.

Contact us

Dr Erin Rayment
Vice-President (Business Development)
e.rayment@qut.edu.au
+61 487 087 818

Dr Patrick Dwyer
Director, Industry Engagement (Health)
p6.dwyer@qut.edu.au
+61 7 3138 9411

The University of Queensland

www.uq.edu.au

The University of Queensland (UQ) is one of Australia's leading research and teaching institutions. We strive for excellence through the creation, preservation, transfer and application of knowledge. For more than a century, we have educated and worked with outstanding people to deliver knowledge leadership for a better world.

UQ ranks among the world's top universities, as measured by several key independent rankings, including the U.S. News Best Global Universities Rankings 2023 (36), the Performance Ranking of Scientific Papers for World Universities 2023 (37), CWTS Leiden Ranking 2023 (35), QS World University Rankings 2024 (43), Academic Ranking of World Universities 2023 (51), and Times Higher Education World University Rankings 2024 (70).

213 Fellows of Australia's 5 learned academies – AAS, AAHMS, ASSA, ATSE, and AAH – are UQ staff (including honorary and adjunct appointments) and emeritus professors.

UQ is one of only 4 Australian members of the global Universitas 21, a founding member of the Group of Eight (Go8) universities, and a member of Universities Australia.

UQ has a strong focus on teaching excellence, having won more Australian Awards for University Teaching (AAUT) than any other university in the country and attracting the majority of Queensland's highest academic achievers, as well as top interstate and overseas students.

We are committed to excellence in learning experiences and outcomes for our students.

The University's outstanding 332,000+ alumni include a Nobel laureate, an Academy Award winner, and leaders in government, law, science, public service and the arts. The University celebrates its alumni as its greatest assets. Their achievements reflect well on the University and, in return, we work hard to strengthen our reputation.

Contact us

Ms Shannon Willoughby
Executive Director
s.willoughby@uq.edu.au
+61 411 255 480

Ms Lucy Merritt
Senior Principal
l.merritt@uq.edu.au
+61 482 063 973



UniQuest Pty Limited

<https://uniquest.com.au/>

About us

UniQuest is the commercialisation company of UQ. In partnership with UQ's researchers, we create impact through the commercialisation of UQ intellectual property. UniQuest's track record positions UQ as the leader of research commercialisation in Australasia. Our expertise includes IP protection and management, start-ups and licensing, commercial negotiation and access to investment capital.

Contact us

Dr Craig Belcher
Head of Life Sciences
c.belcher@uniquest.com.au
+61 407 637 853

Mr David Markwell
Senior Director, Commercialisation
- Lifesciences
d.markwell@uniquest.com.au
+61 428 385 705

Dr Tamsin Terry
Senior Director, Commercialisation
- Lifesciences
t.terry@uniquest.com.au
+61 409 156 555

Dr Idalia Ridley
Director, Commercialisation – Life Sciences
i.ridley@uniquest.com.au
+04 475 735 781

Dr Yvonne Booth
Senior Associate,
Commercialisation – Lifesciences
y.booth@uniquest.com.au
+61 439 292 633

Institute for Molecular Bioscience

www.imb.uq.edu.au

About us

The Institute for Molecular Bioscience (IMB) is Australia's #1 research institute. Created through merging a molecular and cellular biology centre with a drug discovery centre, IMB capabilities span genomics, biology and chemistry, encompassing basic discovery science to translational research. IMB tackles the diseases that plague people, animals and crops and has a track record of partnering to deliver translational outcomes, with spinouts including Protagonist Therapeutics and Inflazome. Expertise includes pharmacogenetics and statistical genetics, AI diagnostics, drug discovery and medicinal chemistry, preclinical research models and human studies. Disease foci include cardiovascular disease (stroke and heart attack), neurological disorders (Alzheimers, Parkinsons, and mental health), inflammation (particularly inflammasome-driven), endometriosis, antimicrobial resistance, genetic diseases, cancer, pain, and vaccines and diagnostics (bacterial, viral, parasitic).

Contact us

Professor Mark Blaskovich
Director of Translation and Industry Engagement
m.blaskovich@uq.edu.au
+61 4 1495 5380

The Queensland Emory Drug Discovery Initiative

www.qeddi.com.au/

About us

The Queensland Emory Drug Discovery Initiative (QEDDI) is a small molecule drug discovery and development group dedicated to translating academic biomedical research into new medicines.

QEDDI is a business unit of UniQuest and the only example of its kind in an Australian university. QEDDI has an industry-experienced team dedicated to advancing biomedical research into new drug candidates to enable commercial partnerships and accelerate new drug development.

Contact us

Dr Andrew Harvey
Head of QEDDI Strategic Partnerships
a.harvey@uniquest.com.au
+61 427 389 495

Mrs Laura Kearney
Business Development Manager – QEDDI
l.kearney@uniquest.com.au
+61 414 559 072

BASE mRNA Facility

<https://www.basefacility.org.au>

About us

The BASE mRNA facility, at AIBN, UQ, helps scientists build new mRNA vaccines and therapies. We have experience making hundreds of mRNAs, and offer end-to-end services, including design, manufacture and LNP formulation of mRNA. We also provide off-the-shelf mRNA reagents and helpful advice. BASE scientists have a passion for mRNA. Our team have research interests in manufacturing and process development, bioinformatic design and analysis, and mRNA drug discovery and development.

Please contact us if you would like support developing new mRNA vaccines and therapies. The BASE facility has experience producing hundreds of mRNAs and offers end-to-end services, including the design, manufacture, and LNP formulation of mRNA for research and pre-clinical use, with clinical mRNA manufacturing facilities set to open in 2024.

Contact us

Professor Timothy Mercer
Director
t.mercer@uq.edu.au
+61 426 615 553

Faculty of Science

www.science.uq.edu.au/home

About us

The Faculty of Science has a world-class reputation, ranking #4, #6 and #10 in the world for agriculture; for environment and ecology; for Biotechnology respectively. The Faculty has made significant achievements in microbiology, plant and animal science, and biology and biochemistry. Their biotechnology research spans several areas, including antibody engineering for cancer and inflammatory diseases, drug delivery systems, tissue engineering, vaccine design, and the development of diagnostic assays for various pathogens. There is also a focus on the discovery and development of antibiotics, antivirals, antifungals and biopesticides. Professor Ian Frazer and Dr Jian Zhou's groundbreaking development of the cervical cancer vaccine took place in UQ's Faculty of Science.

Most of this capability is housed across various schools including:

The [<https://smp.uq.edu.au/>] School of Mathematics and Physics have world class capabilities in quantum technology and houses the Center for Quantum Biotechnology [<https://smp.uq.edu.au/research/research-centres/arc-centre-excellence-quantum-biotechnology>] this aims to create paradigm-shifting quantum technologies to observe biological processes and transform our understanding of life.

The [<https://scmb.uq.edu.au/>] School of Chemistry and Molecular Biosciences, focused on themes related to vaccine technology, biomolecular chemistry, Infection and Immunity, medicinal chemistry, molecular genetics and genomics, nanotechnology, materials chemistry, structural biology and biochemistry.

The [<https://agriculture-food-sustainability.uq.edu.au/>] School of Agriculture and Food Sustainability: brings together expertise in agriculture, agribusiness, plant and crop sciences, animal science, soil science, food science, and international and rural development. Key capabilities are the Food and Beverage Accelerator or the ARC Centre of Excellence for Plant Success in Nature and Agriculture

The [<https://veterinary-science.uq.edu.au/>] School of Veterinary Science: covers a broad range of research interests, encompassing nearly all disciplines of veterinary science and comprising basic, applied and translational research, including a comparative oncology program to evaluate and test new cancer treatments in animals before entering in phase-I human clinical trials.

The [<https://aidrc.org.au/>] Australian Infectious Disease Research Centre investigates the mechanisms by which infectious agents cause disease, develops therapeutics and vaccines to prevent infectious disease, translates discoveries to improve human health and provides an emergency response resource for outbreak management.

The [Centre for Marine Science - University of Queensland (uq.edu.au)] Centre for Marine Science. expertise spans policy, management, conservation and ecology; genomic, molecular and physical sciences; and engineering and advanced technologies. These are applied in the following areas: Innovation and blue economies, Coastal and ocean systems, Coral reefs, Society and changing oceans.

Contact us

Professor Avril Robertson

Associate Dean Research and Deputy Executive Dean

a.robertson3@uq.edu.au

+61 413 195 040

Australian Institute for Bioengineering and Nanotechnology (AIBN)

www.aibn.uq.edu.au/

About us

AIBN is world-renowned in mapping the processes of biology at the nanoscale. We work at the gene, genome and protein level to manufacture new materials, medicines and fuels. We partner with industry to lead advances in vaccine development for chronic and infectious diseases, mRNA design and production, precision nanomedicine, drug design and delivery, advanced biomanufacturing and biomass conversion, and stem cell and regenerative engineering.

Contact us

Professor Alan Rowan
Institute Director
alan.rowan@uq.edu.au
+61 439 228 663

Queensland Brain Institute

gbi.uq.edu.au/

About us

The Queensland Brain Institute (QBI) is a world-leader in brain research, devoted to a fundamental understanding of how the brain works, focusing on five key areas - dementia and ageing, brain injury, brain development and plasticity, mental health and cognition and behaviour.

Contact us

Professor Pankaj Sah
Director
pankaj.sah@uq.edu.au
+61 7 3346 6311

Translational Research Institute

www.tri.edu.au/translational-research-institute-australia

About us

The Translational Research Institute (TRI) is a unique, Australian-first initiative of 'bench to bedside' medical research. TRI combines clinical and translational research to advance progress from laboratory discovery to application in the community.

The TRI facility gives early-phase start up biotech companies time to establish, build, test and develop their products and provides a supportive environment to advance medical discoveries to healthcare solutions. In response to the lack of scale-up manufacturing facilities in Australia, TRI has secured funding to build Translational Manufacturing@TRI (TM@TRI), Australia's first scale-up biomedical manufacturing facility supporting mid-stage biotech companies as they mature and manufacture products for Phase II and III clinical trials studies.

Contact us

Professor Scott Bell
CEO
scott.bell@tri.edu.au
+61 410 718 296

Ms Glenda Colburn
Industry Development & Tenancy
Manager
glenda.colburn@tri.edu.au
+61 406 915 515

David Crowley
General Manager – Translational
Biomedical Manufacturing
david.crowley@tri.edu.au
+61 450 070 722

University of the Sunshine Coast

Clinical Trials

www.usc.edu.au/community/unisc-clinical-trials/participate-in-a-clinical-trial

About us

University of the Sunshine Coast (UniSC) Clinical Trials is an expansive network of five sites in Queensland (Australia), committed to improving access to clinical trials across our communities.

Our network of sites conducts studies in house and through a decentralised clinical trial (DCT) capability with primary, specialist, and urgent care in metropolitan and regional communities. A team of over 125 professionals including 22 medical investigators supports industry sponsors to undertake early to late phase including healthy volunteer confinement protocols. We conduct trials in a range of indications and therapeutic areas including vaccines, infectious disease challenge models (malaria), chronic diseases, haematology, and oncology.

Contact us

Mr Lucas Litewka
Director
llitewka@usc.edu.au
+61 429 930 449

Mr Tom Bailey
Senior Project Manager
tbailey@usc.edu.au
+61 473 614 461

Our businesses

Our delegates at BIO2024 include a range of biomedical businesses, service providers, manufacturers and biomedical expertise.

360biolabs

www.360biolabs.com/

About us

360biolabs stands as the preeminent specialty laboratory in the APAC region, offering a comprehensive suite of services to meet all your global clinical trial needs. Our expertise encompasses pharmacokinetic (PK) analysis across biologics, small molecules, peptides, and proteins, as well as a diverse array of pharmacodynamic (PD) endpoints such as flow cytometry, biomarkers, molecular assays, ELISpot, and virological endpoints, including neutralization along with central lab services in a rigorously quality-assured environment compliant with GLP, GCP, and ISO/IEC 17025 standards.

Backed by a team of seasoned scientific and QA professionals, we ensure the highest standards of scientific rigor, data integrity, and regulatory compliance across all stages of clinical development. Countless top global pharmaceutical and biotech companies trust us as their partner of choice. Our unwavering commitment to precision, punctuality, and regulatory excellence accelerates the delivery of your therapeutic breakthroughs to patients worldwide.

Contact us

Angela Lutnick
EVP, Commercial
Angela.lutnick@360biolabs.com
+61 400 641 333

Alliance Pharma Pty Ltd trading as Resolian

www.resolian.com

About us

Resolian is a leading global Bioanalytical CRO providing specialized services in GxP and non-regulated bioanalysis, drug metabolism/pharmacokinetic (DMPK), and GMP CMC analytical and materials science. Comprised of the former Alliance Pharma Inc, Drug Development Solutions Ltd, and Denali Medpharma labs and powered by a team of more than 500 experts across the US, UK, Australia, and China, Resolian supports pharma and biotech companies' programs throughout the entire drug development continuum.

Resolian's specialized solutions include small and large molecule LC-MS/MS bioanalysis, PK immunoassays for large molecules, immunogenicity, biomarkers, cell-based assays, and drug metabolism. These solutions are delivered through Resolian's dedicated global laboratories, equipped with state-of-the-art technology and ready to meet client needs for preclinical studies as well as regional or global clinical programs.

We are committed to delivering high-quality results and ensuring compliance with regulatory requirements. Its team of experts works closely with clients to develop customized solutions for each specific program requirements. A trusted partner for pharmaceutical and biotech companies seeking specialized support in drug development, Resolian's extensive expertise, advanced technology, and commitment to quality combine to fully deliver for companies of all sizes and at any stage of the drug development process.

Contact us

Dr Ryan Klein
Vice President, Business Development, US and Australia
rklein@resolian.com
+1 919 801 3146

Amivas Australia Pty Ltd

www.amivas.com

About us

AMIVAS is a US, Australian, and European joint venture focused on the development and commercialisation of therapeutics for the treatment of life-threatening diseases with offices in the US, Australia and Ireland. AMIVAS manufactures in North America and our partners in Canada, USA and Europe package and supply our product to hospitals and patients in need.

AMIVAS' vision was formed in response to the urgent need for a US and Europe- based firm to assume responsibility for the manufacture and distribution of Artesunate, for the treatment of severe malaria after quinidine gluconate was discontinued in 2019. With the US Food and Drug Administration (FDA) approval of its first commercial product on May 26, 2020, AMIVAS is proud to join the global effort to fight and eradicate malaria.

Contact us

Ms Barbara Kienast

Senior Director

barbara.kienast@amivas.com

+61 411 560 771

ARM Hub

www.armhub.com.au

About us

ARM Hub is Australia's first manufacturing research and development organisation and an independent, not-for-profit innovation centre with a mission to accelerate the industry's uptake of next-generation advanced technologies. This includes robotics, artificial intelligence and design-led manufacturing.

Contact us

Mr Samuel Jesuadian

Chief Operations Officer

samuel.jesuadian@armhub.com.au

+61 457 020 298

Beyond Drug Development

www.beyonddrugdev.com

About us

Beyond is an Australian based privately owned early phase clinical research organization (CRO) supporting small to medium biotech and pharmaceutical companies across the globe. With a team averaging 20 years' experience in Early Phase research, we offer dedicated and innovative support to our clients whether in the preclinical drug development stage, or moving right through to the clinic and "Beyond".

Contact us

Amelia Beshara
Co-Founder and Director
amelia.beshara@beyonddrugdev.com
+61 492 143 920

Louise Moore
Co-Founder and Director
Louise.moore@beyonddrugdev.com
+61 417 196 745

BIO-BKN

www.biobkn.com.au

About us

BIO-BKN Pty Ltd is a medical device company committed to delivering clinically proven, cost-effective products allowing patients to actively heal and return to full activity sooner and safer following debilitating wound, ligament and tendon injuries. Bio BKN has developed a proprietary marine collagen platform technology with unique and versatile capabilities in wound care and orthopaedic applications. Its lead prototype product, a 3D printed marine collagen mesh for wound products and advanced tissue engineering applications will address modern healthcare needs. Bio BKN is seeking support to expand our platform to the next stage of development including further animal studies and generating data required for regulatory approvals in target markets.

Contact us

Dr Bhanu Manickavasagam
Chief Executive Officer
BioBKN@outlook.com
+61 428 886 555

Biomecentric Pty Ltd

<https://www.biomecentric.com.au/>

Contact us

Shaun Roux
CEO
shaun@biomecentric.com.au
61424620168

Biostate Pty Ltd

www.biostate.com.au

About us

Professional Director and Strategic Advisory services in life sciences and the health sector.

Contact us

Mr Mario Pennisi
Managing Director
Mario@biostate.com.au
+61 409 763 817

Brandon Capital

www.brandoncapital.vc

About us

Brandon Capital is ANZ's leading life science venture capital firm that supports the commercialisation of promising medical research into therapies that generate returns and improve patients' lives.

With 25 active companies in its portfolio and over \$1 billion FUM, Brandon has taken a leading role in transforming world-leading science into world-leading businesses.

Unique deal-sourcing model that offers Brandon Capital proprietary deal flow for the nation's most innovative biotechs, and positions the firm as an experienced partner to support teams from idea to IPO on their company-building journeys.

Contact us

Dr Goslik Schepers
Snr Investment Manager
gschepers@bcpvc.com
+61 449 250 430

Brisbane Economic Development Agency

<https://choose.brisbane.qld.au/>

About us

Brisbane Economic Development Agency (BEDA) drives investment demand for the city of Brisbane, Australia.

As Brisbane 's champion - BEDA works with government and private sector organisations to support global investors to leverage economic opportunities within Brisbane. BEDA also works to scale local "first in class" start-ups by fast tracking connections with international partners -capital investment and distribution.

Contact us

Dr John Cowie
General Manager – Investment
jcowie@brisbane-eda.com.au
+61 468 232 349

Ms Lisa Cavallaro
Senior Manager – Investment
lcavallaro@brisbane-eda.com.au
+61 4 17 077 475

CCRM Australia

<https://ccrmaustralia.com.au/>

About us

CCRM Australia accelerates the commercialisation of regenerative medicine therapies and related technologies. We provide specialist expertise, funding opportunities and connections between industry, clinicians, researchers,

Queensland delegate directory

and other key stakeholders. CCRM Australia offers a number of market consulting services to understand and validate the potential of their technology, such as identifying problems and unmet needs, determining the ideal customer profile and market size, understanding the competitive landscape and creating a Target Product Profile. Our services extend to address any challenges that lie along the route to market from preclinical, clinical trials, process development and cGMP manufacturing.

Contact us

Dr Natasha Korica
Business Development Associate
n.korica1@uq.edu.au
+61 434 393 839

Clinials Global Pty Ltd

<https://www.clinials.com/>

About us

Clinials helps researchers design patient centric trials and complete their patient recruitment.

The AI-powered platform is a copilot that offers continuously refined, updated, and expanded tools. This tool was designed to prioritize the creation of clear, patient-oriented materials in plain language, ensuring cultural diversity and localization (including multiple languages). It is also used for conducting protocol analysis, communicating with stakeholders, feasibility studies, and more. Employing a dynamic, holistic participant recruitment solution early in the life of a trial, could save millions of dollars.

Contact us

Mrs Maree Beare
CEO
maree.beare@clinials.com
+61 414 832 066

Miss Marjolijn Kindt
Head of Business Operations
mkindt@clinials.com
+61 432 973 914

Cytiva

<https://www.cytivalifesciences.com/en/au>

About us

Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. We have a rich heritage that can be traced back of years, and recently welcomed the life sciences business of Pall into our family.

Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, novel cell and gene therapies, and new technologies, such as mRNA. By uniting the life sciences business of Pall with Cytiva, we can better serve our customers and provide them with the technologies and expertise needed to go from pre-clinical research to commercial production.

Mr Jon Ince
General Manager
jon.ince@cytiva.com

Mr Stephen O'Sullivan
Business Development Manager ANZ
stephen.osullivan@cytiva.com
+61 466 394 237

Data & Knowledge Enterprise (DKE) Pty Ltd

<http://www.dkecompany.com.au/>

About us

We are a data and AI service company, optimized for Generative AI helping small and large businesses. At DKE, we believe data and AI is for everyone and organizations deserve access to its transformative potential. That's why we've developed a service-based model that makes AI accessible, affordable, secure and easy to use for businesses of all sizes.

Contact us

Roozbeh Derakhshan
Director
roozbeh@dkecompany.com.au
+ 61 413 343 797

De Motu Cordis Pty Ltd

<https://demotucordis.co/>

About us

De Motu Cordis Pty Ltd (DMC) is producing a needle-free inhalable adrenaline device for the urgent treatment of anaphylaxis - Where Every Second Counts. This is the first product of a platform technology of drug delivery for medical emergencies.

We have grown to a clinical stage company with in-house expertise in pharma, engineering and emergency care medicine. We are collaborating with best-in-class at a global level having developed a new dry powder inhaler from the ground up.

Contact us

Professor John Fraser
Founder & Chief Medical Officer
john.fraser@demotucordis.co
+61 407 128 039

FB Rice

<https://www.fbrice.com.au/>

About us

Since being founded more than 70 years ago, FB Rice become Australia's most trusted intellectual property firm with offices across the country and a well-established presence in New Zealand and South-East Asia.

Today, we combine world-leading expertise across biotechnology, chemistry, computer and electrical sciences, engineering and medical devices with integrity and a determination to help clients achieve their goals.

We pride ourselves on our expertise and our ability to make our clients feel comfortable and respected at every stage of the process. We're real people who build partnerships based on trust by being open, approachable and totally focused on clients' needs.

At FB Rice, we champion innovation and create value.

Contact us

Dr David Loch
Partner
dloch@fbrice.com.au
+61 402 064 120

Fovero Therapeutics

<https://www.foverotherapeutics.com.au/>

About us

Fovero Therapeutics is a pre-clinical stage biotechnology company with a portfolio of novel immunotherapies for treating immuno-oncology resistant cancers and autoimmunity. The company's lead immunotherapy, FT002, has potential to be a first-line, single agent therapy for colon cancer, which has a great unmet need.

In 2020, the total population of MSS patients, in 8 major markets, was approximately 800,000. Assuming, ~50% resistance to current therapies, and cost of US\$224K/patient, the total market opportunity would be ~US\$8.9B. It would also address an unmet need for triple negative breast cancer.

Fovero Therapeutics has raised AU\$0.5M in non-dilutive funds from Brandon Biocatalyst, AU\$0.69M from philanthropy and US\$0.75M from US DoD to progress the understanding of FT002's mode of action. FT is seeking US\$12

Contact us

Associate Professor Michelle Wykes
Founder/ CSO
Michelle.Wykes@qimrberghofer.edu.au
+61 402 708 880

Gelomics

<https://www.gelomics.com/>

About us

Gelomics accelerates drug development by enabling pharmaceutical companies to grow human tissue models as an ethical, cost-effective, and highly predictive alternative to animal experiments. Addressing a US \$50bn+ market opportunity, the company has achieved significant traction in 22 international markets, acquiring 300+ return customers with >80% demo-to-sales conversion and >20% MoM revenue growth. Gelomics is actively seeking distributors, customers, investors, and strategic partners to support our strategic entry in the US market.

Contact us

Dr Christoph Meinert
CEO
christoph.meinert@gelomics.com
+61 450 177 179

Dr Peter Levett
COO
peter.levett@gelomics.com
+64 276 880 009

Graythan Regulatory Services Pty Ltd

<https://www.graythanregulatoryservices.com>

About us

Graythan Regulatory Services (GRS) was established in 2017 to offer consulting services to support the biopharmaceutical industry. Our team has over 75 years of collective experience in the pharmaceutical industry with a specialty in readying stalled or legacy products to swiftly enter the clinic or gain marketing approval.

Over time, we grew to establish one of Brisbane's only non-university-based Institutional Biosafety Committee (IBC) to provide classified advice, and formally review license applications on gene technology in Australia before submitting them for the Office of Gene Technology Regulator (OGTR) evaluation.

Our beginnings started when our founder saw the need for expert advice on regulatory and commercialisation pathways for emerging biotechnology. His wealth of experience in drug and vaccine development built the foundations for GRS to thrive.

Contact us

Mr William Browning-Zonneveld
Regulatory Affairs Manager
william.browning-zonneveld@graythanregulatoryservices.com
+61 422 796 685

HopgoodGanim Lawyers

<https://www.hopgoodganim.com.au/>

About us

HopgoodGanim Lawyers is a leading Australian mid-tier legal firm. We are recognised for the exceptional outcomes we deliver to our clients in our key priority markets and our superior approach to client service. Our firm includes over 300 staff with 40+ partners and we operate nationally and internationally with a focus on Asia from our two key locations of Brisbane and Perth.

Brett Nelson is a Director - Patents (USA qualified) in HopgoodGanim's Intellectual Property, Technology and Cyber Security team.

He is highly experienced in complex IP portfolios and all phases of the patent life cycle, including patent preparation and prosecution, client counselling, due diligence for acquisitions and divestitures. With over twenty years of experience across Europe, China, Greater Asia, Australia and the United States, Brett is uniquely placed to assist clients in building and understanding IP portfolios.

Contact us

Mr Brett Nelson
Director – Patents
b.nelson@hopgoodganim.com.au
+61 7 3024 0307

James & Wells Intellectual Property

<https://www.jamesandwells.com/au/>

About us

Our life sciences team is consistently regarded as the leading choice for developing and implementing IP strategy by some of Australasia's most innovative universities, start-ups, and research organisations.

James & Wells has an experienced team of life science specialists, with proven research experience across a range of life sciences including immunology, gene therapy, antibodies, cell therapies, synthetic medicinal chemistry, drug development and repurposing, cell biology, microbiology, vaccines and diagnostics.

Through defending the patent rights of our clients before the courts and patent offices of both Australia and New Zealand we are uniquely placed to advise innovators on established strategies for success. In the ever-evolving life sciences sector, our team also have the experience, expertise and confidence to carve out effective new strategies for overcoming complex hurdles in newly developing areas.

In order to keep abreast of industry trends and be at the forefront of life sciences innovation, James & Wells is an active member of AusBiotech, Life Sciences Queensland, Biotech New Zealand and Natural Health Products NZ. We understand the life sciences industry of today, and where it will be, tomorrow.

Contact us

Dr Andrew Clarke
Partner, Patent Attorney
andrew.clarke@jamesandwells.com
+61 402 436 601

Kimaritec Pty Ltd

<https://www.linkedin.com/company/kimaritec-pty-ltd/>

About us

Kimaritec is developing new therapies for cancer, by manipulating the cancer cell's protein recycling pathway to drive protein degradation of critical oncproteins. Cancer remains a disease with high unmet medical need, with many patients succumbing to tumours which become unresponsive to current therapy. Clinicians and patients are looking for new approaches to eradicate or slow the progression of cancer. Kimaritec is taking a novel approach to selectively degrade proteins important for cancer growth and metastasis. It is hoped that by harnessing this novel protein degradation pathway, Kimaritec will develop new anti-cancer therapies.

Contact us

Dr Mohanan Maharaj
Head of Biology
mmaharaj@kimaritec.com
+61 469 876 549

<https://www.lsq.com.au>

About us

Life Sciences Queensland Limited (LSQ) is a Queensland peak body that offers opportunities for industry stakeholders to come together and cooperate to grow their businesses and help create a dynamic, internationally competitive and sustainable life sciences industry in Queensland, Australia.

LSQ is helping to shape the strategic direction of the industry in Queensland and influence public policy. LSQ also provides members with tools, services, market intelligence and access to an international network of life sciences organisations with the aim of identifying new business opportunities and accelerating business growth.

Contact us

Professor Trent Munro
LSQ Board Chair
Chair@lsq.com.au
+61 499 880 791

Dr Sarah Meibusch
LSQ Director
smeibusch@one-ventures.com
+61 409 595 408

Macrobiome Therapeutics

<https://www.macrobiometherapeutics.com>

About us

Macrobiome Therapeutics Pty Ltd is a company harnessing the therapeutic potential of hookworms and other parasitic helminths to develop drugs for the treatment of immune-mediated inflammatory diseases. The company is based in tropical North Queensland, Australia, an area of enormous biodiversity. Macrobiome Therapeutics was founded by Professor Alex Loukas and Dr Paul Giacomin of the Australian Institute of Tropical Health and Medicine at James Cook University, and brings together a number of leading international medical research teams to develop novel therapeutics for chronic diseases with limited treatment options, such as IBD, T2D, and non-healing wounds.

Contact us

Professor Alexander Loukas
CEO
alex.loukas@macrobiometherapeutics.com
+61 434 025 607

Michael Buck Intellectual Property

<https://www.mbigp.com.au/>

About us

Michael Buck IP is an independent, boutique intellectual property firm, based in Brisbane Australia.

We help creative, innovative and inventive people and businesses to protect, defend and commercialise their intellectual assets. Our clients range from local companies and individual inventors to start-ups, international corporations, universities and research organizations.

Contact us

Dr David Tso
Senior Associate - Patent Attorney
david@mbip.com.au
+61 402 797 323

Microba

<https://www.microba.com>

About us

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

Contact us

Professor Trent Munro
SVP Therapeutics
trent.munro@microba.com
+61 499 880 791

Nucleus Network

<https://www.nucleusnetwork.com>

About us

Nucleus Network, Australia and USA's Premier Phase I Specialists

Nucleus Network is the world's only Phase I clinical trial specialist with clinics in both Australia and the United States. We have three units with 220+ beds and conduct a full suite of complex early phase clinical trials including FIH with biomarkers/patients, DDI, TQT, BA, Biosimilars, Vaccine and Renal/Hepatic Impairment. We are opening a new clinic in Sydney, and expanding our Melbourne clinic. By early 2025 we will be over 300+ beds and have access to ~80% of the Australian population for recruitment!

Operating in the two global regions where a majority of Phase I studies are performed allows our sponsors to exceed their Phase I value inflection targets rapidly, efficiently and meet international quality standards allowing progression into Phase 2 and beyond.

The Australian clinical trial landscape allows global biotechs to advance their clinical programs faster, easier (No IND), cheaper (43.5% Tax Incentive) and to the same quality standard (ICH/GCP) as studies performed in the USA.

Contact us

Mr Chris Hickey
Chief Business Development Officer
c.hickey@nucleusnetwork.com
+1 44 368 558 00

OneVentures

<https://one-ventures.com.au/>

About us

OneVentures is an Australian based Venture Capital firm with >\$750m under management.

OneVentures is a later-stage Venture Capital Firm, focused on scaling Technology and Healthcare companies through growth equity and credit.

Contact us

Sarah Meibusch
Partner
smeibusch@one-ventures.com
+61 409 595 408

Pizzeys Patent & Trade Mark Attorneys

<https://www.pizzeys.com.au/>

About us

Since 1981, Pizzeys have been providing practical, personalised and responsive service to protect and enforce patents, trade marks and designs. The same committed service is provided in Australia, New Zealand and Singapore.

Our core business resides in establishing, maintaining and enforcing intellectual property rights in Australia, New Zealand and Singapore. Our qualified attorneys are dedicated to achieving the highest of standards. We understand the need for high quality and responsive service.

Contact us

Dr Justin Sweetman

Principal

jsweetman@pizzeys.com

+61 409 866 394

Qbiotics Group

<https://www.QBiotics.com>

About us

Qbiotics is a public unlisted Australian life sciences company that discovers and develops novel small molecule drug candidates. Our current clinical focus is solid tumors and debilitating chronic wounds. Qbiotics' lead oncology molecule, tigilanol tiglate, is an intratumoral treatment (usually single injection) for a broad range of solid tumors.

Tigilanol tiglate is very effective as a monotherapy, murine data also supports the potential of tigilanol tiglate in combination with checkpoint inhibitors, chemotherapy and radiotherapy. Tigilanol tiglate is currently in human clinical Phase II development for the treatment of soft tissue sarcomas (USA) (awarded FDA Orphan Drug Designation) and head and neck cancers (UK and Australia).

Qbiotics' business model is to develop drug candidates to proof of concept/human clinical Phase II and then partner for late-stage development and commercialisation. We use veterinary real world disease models (commencing at preclinical stage of development) to validate our technology and de-risks/inform early clinical stage human development. Tigilanol tiglate has secured regulatory and commercial validation as a veterinary product STELFONTA® for canine mast cell tumors, reporting a 75% Complete Response (CR) rate for a single injection in an FDA-CVM pivotal canine trial.

Contact us

Roberta Bozzoli

roberta.bozzoli@qbiotics.com

+61 411 157 464

Dr Victoria Gordon

victoria.gordon@qbiotics.com

+61 418 453 737

Sanofi

<https://www.sanofi.com>

About us

The Translational Science Hub connects world-class researchers in Queensland with Sanofi scientists in France and the US, creating a first-of-its-kind, global scientific community focused on mRNA technology and translational science. The Translational Science Hub is proudly supported by Sanofi, Griffith University, The University of Queensland and the Queensland Government.

Our main focus areas:

- Optimise mRNA platform technology: This includes improving mRNA as a vaccine technology that can be used for multiple vaccine candidates and for therapeutics.
- Bring together the local academic and industry network: By having a R&D presence in Australia, Sanofi is able to work more closely with the local scientific talent and help create a strong and sustainable scientific ecosystem.
- Advance the development of vaccine candidates: new vaccines for Influenza, RSV, Chlamydia and Acne are being explored in Queensland.

Contact us

Dr Iris Depaz
Managing Director
iris.depaz@sanofi.com
+61 439 254 798

Servatus Biopharmaceuticals

<https://www.servatus.au>

About us

Servatus is an Australian biopharmaceutical company developing dual drug platforms, aiming to deliver first-line and adjunct treatments for select autoimmune, gastrointestinal and dermatological conditions.

Servatus provides:

- Live biotherapeutics design, development, and manufacturing
- Microbiome based therapies for auto-immune conditions
- Clinical stage biotech company
- Proprietary manufacturing process and large scale continuous manufacturing facility with high level of automation
- Over the counter products, commercially available for skin conditions.

Contact us

Mr Mark Williams
CEO
mark.williams@servatus.com.au
+61447951682

Mr Nicolas Pichon
Head of Production
nicolas.pichon@servatus.com.au
+61 406 346 232

Southern RNA

<https://www.southernrna.com.au>

About us

Discover Southern RNA, Australia's pioneering Contract Development and Manufacturing Organisation (CDMO) specialising in RNA-based therapeutics and vaccines. Integrate the rapid design turnover of RNA-based drugs with Southern RNA's manufacturing platform and Australia's exceptionally streamlined approval processes to accelerate your path from discovery to clinical trials. Partner with us to fast-track your development journey and leverage the full opportunity of Australia's R&D tax incentive.

Southern RNA has built a team of industry and RNA experts together with a robust pharmaceutical quality system to support a wide range of services, including custom RNA production, tech transfer, engineering run, and clinical-grade manufacturing, analytical assay development (design, qualification, validation), upstream and downstream process development, raw material manufacturing and supply (E. coli cell bank, pDNA, Cap analog).

Contact us

Dr Romain Tropee
Head of Science and Technology
romain.tropee@southernrna.com.au
+61 406 762 130

Spruson and Ferguson

<https://www.spruson.com/>

About us

Spruson & Ferguson is a leading intellectual property firm providing a range of IP services throughout the Asia-Pacific region from our offices in Australia (Brisbane, Melbourne, Sydney), China, (Beijing, Hong Kong), Indonesia, Malaysia, Philippines, Singapore and Thailand.

With a combined team of over 480 people, including patent attorneys, trade mark attorneys and IP lawyers, Spruson & Ferguson is one of the only IP firms with true regional capability, knowledge and experience.

Contact us

Peter Brown
Chemistry & Life Sciences
Principal
peter.brown@spruson.com
+61 4 525 62167

Thermo Fisher Scientific

www.thermofisher.com/patheon

About us

Thermo Fisher Scientific provides industry-leading pharma services for drug development, clinical trial logistics, and commercial manufacturing through our Patheon™ brand. We partner with customers in the pharmaceutical, biotech, and life sciences industries as their trusted CDMO to deliver medicine to patients faster. We believe that doing this successfully not only requires science, technology, and world-class expertise, but also requires a strategic partnership—bonded by key elements such as trust, communication, and collaboration. We embed these elements into every operation, interaction, and step in the drug development journey.

With more than 60 locations around the world, we are committed to providing integrated, end-to-end solutions across all phases of development. Our pharma services include API, biologics, viral vectors, formulation, clinical trials solutions, logistics services, and commercial manufacturing, and packaging. We couple our scientific and technical excellence in these areas with a strategic partnership, to provide customers of all sizes access to a global network of facilities and dedicated experts across the Americas, Europe, Asia, and Australia.

At Thermo Fisher Scientific, we understand that developing novel therapies and moving them from discovery to patients is a complex, high-risk process. Every customer has different needs, and every newly discovered drug has a unique pathway to reach the market. As a global, full-service CDMO, we help our partners bring innovative molecules and life-changing therapies to market as efficiently and safely as possible.

Contact us

Director Business Management
majella.clifton@thermofisher.com
+61 456 876 988

Thomson Geer Lawyers

<https://www.tglaw.com.au>

About us

We have an in-depth understanding of the life sciences and health sector in Australia and globally.

Our specialist lawyers are experienced in providing advice with respect to the broad range of issues facing this complex and highly regulated industry.

We provide legal services to the broader industry including aged care providers, retirement village operators, affiliated health organisations, primary health networks, public and private hospitals, medical research institutes, start-up companies, spin off companies, private and listed entities, government, universities, international trial sponsors, collaborative research groups, institutions and principal investigators, biotechnology, medical device and pharmaceutical organisations.

This gives us a broad perspective on the whole industry and the range of interactions between sectors.

Contact us

Mr Anthony Conaghan
Partner
tconaghan@tglaw.com.au
+61 419 464 002

Ms Katrina Chambers
Partner
kchambers@tglaw.com.au
+61 497 210 127

UltraThera

<https://www.ultrathera.com.au>

About us

UltraThera is developing therapeutic ultrasound to restore brain function, with Alzheimer's disease as the lead indication. We are at an early clinical stage with proof-of-concept safety using our first generation therapeutic ultrasound system.

We have developed a multimodal therapy that activates the brain's natural immune response and enhances brain cell communication as shown by our extensive preclinical data. The approach has utility across a broad range of neurodegenerative and neurological disorders including delivery of therapeutics to the brain.

Contact us

Dr Rachel de las Heras

Co-Founder

r.delasheras@ultrathera.com.au

+61 402 405 551

Vast Bioscience Pty Ltd

<https://www.vastbioscience.com>

About us

Vast Bioscience is an Australian based preclinical stage biotech company creating safe and effective non-opioid pain relief options for moderate-to-severe acute and chronic pain through the use of its innovative 3D drug discovery technology. With a focus on genetically and clinically validated Voltage-Gated Sodium Channels (VGSCs), Vast Bioscience has potential to participate in addressing one of the largest unmet medical needs.

Vast Bioscience's chemical platform delivers two new classes of VGSC inhibitors, currently in lead optimisation, that promises to significantly improve efficacy. The small molecules have reduced risk of off-target side effects due to their unique 3D shape. Selective Vast Nav1.8 inhibitors promise improved safety allowing higher exposure and thereby better efficacy towards a best-in-class product

A parallel program pursues Vast Nav1.7/Nav1.8 selective VGSC inhibitors which are expected to further improve efficacy through synergy between pain VGSCs (first in class).

Contact us

Dr Wim Meutermans

Chief Scientific Officer

wmeutermans@vastbioscience.com

+61 404 075 465

Vaxxas Pty Ltd

<https://www.vaxxas.com>

About us

Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP).

With success in several human clinical trials involving more than 500 participants, and additional ongoing studies with its global program partners including BARDA (US Government), the Bill and Melinda Gates Foundation and the WHO, the company is advancing its vaccination technology toward commercialization.

Contact us

Mr Doug Cubbin
Chief Financial Officer
dcubbin@vaxxas.com
+61 7 2139 5400



Contact us

Department of State Development and Infrastructure
Biomedical Team
biomedical@dsdilqp.qld.gov.au

Telephone: +61 7 3022 6100